|
|
Article: Study data from D.A. Ignaut et al provide new insights into life sciences.(Clinical report)
- Article from:
- Diabetes Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
According to a study from the United States, "The purpose of this study was to compare pen device-naive patients' preferences for Humalog [R] KwikPen ™ (insulin lispro injection) (Eli Lilly and Company, Indianapolis, IN) to use of a vial and syringe and FlexPen [R] (insulin aspart injection) (Novo Nordisk A/S, Bagsvaerd, Denmark). This open-label, randomized, crossover 1-day study tested the hypotheses that KwikPen was preferred to vial and syringe, and if this was found to be a significant preference, that KwikPen was preferred to FlexPen."
"Accuracy of doses prepared, ease of use via insulin device assessment battery, and preference via insulin device ...